This is a preview of subscription content, log in via an institution to check access.
Notes
This study was supported by an unrestricted educational grant from AstraZeneca.
Conducted in collaboration with Novartis Australia.
This study was supported by Forest Laboratories.
Funded in part by Pfizer UK and Pfizer.
The study was supported by Novartis Pharma GmbH, Germany, with which one of the researchers was affiliated.
Costs (2006 values) were those related to physician visits, serum alkaline phosphatase measurement, drug acquisition and administration, and laboratory procedures. Costs were presented from the perspective of the German Social Health Insurance; costs in the second year were discounted by 5% per annum.
All costs were reported in 2004 values; direct health resource costs for fracture states were discounted at a 3.5% annual rate.
References
Merims D, Balas M, Peretz C, et al. Rater-blinded, prospective comparison: quetiapine versus Clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol 2006 Nov–Dec; 29(6): 331–7
Reference
Orion. New evidence demonstrates early use of Stalevo® improves quality of life and may provide long-term benefits in patients with Parkinson’s disease [media release]. 2006 Oct 31. Espoo: Orion [online]. Available from URL: http://www.orion.fi [Accessed 2006 Dec 9]
Reference
Ondo WG, Silay YS. Intravenous flumazenil for Parkinson’s disease: a single dose, double blind, placebo controlled, cross-over trial. Mov Disord 2006 Oct; 21 (10 Pt 1): 1614–7
Reference
Somaxon Pharmaceuticals Inc. Soniaxon Pharmaceuticals’ SILE-NOR™ demonstrates positive results in its third phase 3 clinical trial in insomnia [media release]. 2006 Nov 20. San Diego (CA): Somaxon Pharmaceuticals Inc. [online]. Available from URL: http://www.somaxon.com [Accessed 2006 Nov 25]
Reference
Mohamed S, Osatuke K, Aslam M, et al. Escitalopram for comorbid depression and anxiety in elderly patients: a 12-week, open-label, flexible-dose, pilot trial. Am J Geriate Pharmacother 2006 Sep; 4(3): 201–9
Reference
National Institute for Health and Clinical Excellence. Dementia: supporting people with dementia and their carers in health and social care. Technology Appraisal Guidance. 2006 Nov; (42): 1–56 [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 Dec 2]
Reference
National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease: includes a review of NICE Technology Appraisal Guidance 19. Technology Appraisal Guidance. 2006 Nov; (111): 1–64 [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 Dec 2]
Reference
ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammato-ry Prevention Trial (ADAPT). PLoS Medicine 2006 Nov: e33 0001-e33 00010. Cambridge: PLoS Clinical Trials [online]. Available from URL: http://www.plosclinicaltrials.org [Accessed 2006 Dec]
Reference
Neil HAW, DeMicco DA, Luo D, et al., CARDS Study Investigators. Analysis of efficacy and safety in patients aged 65–75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006 Nov; 29(11): 2378–84
Reference
Di Marco F, Verga M, Santus P, et al. Effect of formoterol, tiotropi-um, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006 Nov; 100(11): 1925–32
Reference
Kasama S, Toyama T, Hatori T, et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart 2006 Oct; 92(10): 1434–40
Reference
Chuang Y-C, Chiang P-H, Yoshimura N, et al. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperpla-sia. BJU Int 2006 Nov; 98(5): 1033–7
Reference
Dohmen K, Okabe H, Ishibashi H. Regression of hepatocellular carcinoma due to cyclooxygenase (COX)-2 inhibitor. Am J Gastroenterol 2006 Oct; 101(10): 2437–8
Reference
Sciarra A, Silver MR, Agarwal A, et al. Once-monthly darbepoetin alfa maintains hemoglobin levels in elderly patients with chronic kidney disease [abstract]. J Manag Care Pharm 2006 Sep; 12(7): 597
Reference
Hayward AC, Harling R, Wetten S, et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ 2006 Dec 16; 333(7581): 1241
References
Kurth AA, Kotowa W, Fricke FU, et al. Zoledronic acid in the long-term management of Paget’s disease of the bone in Germany — a cost-saving approach? [abstract no. PAR2 plus poster]. Value Health 2006 Nov–Dec; 9(6): A220
Kosa J. An economic evaluation of zoledronic acid treatment in Paget’s disease of bone in the Hungarian health care setting [abstract]. Value Health 2006 Nov–Dec; 9(6): A380
Reference
The Alliance for Better Bone Health. Study of over 33,000 women comparing two most prescribed osteoporosis treatments shows significant difference in hip fracture reduction [media release]. 2006 Nov 17. P&G Pharmaceuticals [online]. Available from URL: http://www.pgpharma.com [Accessed 2006 Dec]
References
Earnshaw SR, Beard S, Lynch NO, et al. A comparison of the cost-effectiveness of bisphosphonates using persistence data from a UK prospective RCT. J Bone Miner Res 2006 Sep; 21Suppl. 1: 416–7
Grima DT, Pasquale MK, Lange JL, et al. Cost-effectiveness of risedronate versus ibandronate: impact of persistence [abstract]. J Bone Miner Res 2006 Sep; 21Suppl. 1: 181
Rights and permissions
About this article
Cite this article
Gerontology Forum. Drugs Aging 24, 73–80 (2007). https://doi.org/10.2165/00002512-200724010-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200724010-00006